卵胞浆内单精子显微注射 中国就医指南

Intracytoplasmic Sperm Injection (ICSI) is not a disease but a highly specialized assisted reproductive technology (ART) performed within the Department of Reproductive Medicine. It involves the direct injection of a single viable sperm into the cytoplasm of a mature oocyte (egg) using micromanipulation techniques under high-powered microscopy. ICSI was first successfully used in 1992 and has since revolutionized the treatment of severe male factor infertility, including azoospermia (absence of sperm in ejaculate), severe oligozoospermia (extremely low sperm count), asthenozoospermia (poor sperm motility), teratozoospermia (abnormal sperm morphology), and cases where prior conventional in vitro fertilization (IVF) failed due to poor or failed fertilization. Pathogenetically, ICSI bypasses natural barriers to fertilization—such as sperm binding to the zona pellucida and fusion with the oolemma—making it indispensable when physiological sperm–oocyte interaction is impaired. It does not correct underlying genetic, hormonal, or anatomical causes of infertility but serves as an effective procedural intervention. Epidemiologically, ICSI accounts for over 70% of all IVF cycles globally, with usage rates exceeding 85% in many high-income countries and rapidly increasing across China due to rising male infertility prevalence, delayed childbearing, environmental exposures, and lifestyle factors. Key risk factors associated with the need for ICSI include varicocele, cryptorchidism, prior chemotherapy or radiation, genetic conditions (e.g., Klinefelter syndrome, Y-chromosome microdeletions), testicular failure, obstructive azoospermia (e.g., post-vasectomy or congenital absence of the vas deferens), and unexplained infertility with prior fertilization failure. While ICSI itself carries minimal physical risk to patients, the broader ART process—including ovarian stimulation, egg retrieval, and embryo transfer—can cause transient discomfort, ovarian hyperstimulation syndrome (OHSS), procedural anxiety, and emotional strain. The psychological burden of infertility and repeated treatment cycles significantly impacts quality of life: patients often report elevated stress, depression, marital tension, financial distress, social isolation, and diminished self-worth. Though successful ICSI pregnancies lead to live births in approximately 30–35% per cycle (varies by age and clinic), cumulative success rates improve with multiple attempts. Importantly, long-term follow-up studies indicate slightly increased risks of certain imprinting disorders and congenital anomalies in ICSI-conceived children compared to naturally conceived peers—though absolute risks remain low and are confounded by underlying parental infertility factors. Comprehensive pre-ICSI counseling, genetic screening (e.g., karyotype, CFTR, Y-microdeletion testing), and psychosocial support are integral to ethical, patient-centered care.

# 卵胞浆内单精子显微注射（ICSI）治疗与费用指南（生殖医学科）

一、非手术/保守/药物/理疗方案

适用于轻中度男性少弱畸精症、不明原因不孕或常规IVF受精失败者。

• •促排卵+精液优化+自然周期监测：含激素六项、AMH、精液常规+形态学+DNA碎片检测，费用 ¥2,800–¥4,500
• •抗氧化联合维生素E/左卡尼汀治疗（3个月）：含精液复查及超声卵泡监测，费用 ¥1,200–¥2,600

二、手术/微创/核心介入方案（ICSI核心治疗）

适用于严重少精、梗阻性无精（术后取精）、非梗阻性无精（需睾丸穿刺）、既往IVF完全受精失败者。

• •全套ICSI周期（含促排、取卵、单精子显微注射、胚胎培养、鲜胚移植）：

- 标准档（进口药物+时差培养+囊胚培养）：¥42,000–¥49,000 - 高端档（PGT-A筛查+玻璃化冻存+解冻移植）：¥68,000–¥85,000

• •术前检查费（必查）：染色体核型+Y微缺失+精液全项+传染病八项+宫腔镜（必要时），合计 ¥3,200–¥5,600

三、特殊复杂方案

复发性种植失败、高龄（≥40岁）、反复生化妊娠者：加用免疫调节（如泼尼松+低分子肝素）、子宫内膜容受性检测（ERA）、宫腔灌注等，费用 ¥8,000–¥15,000/周期

四、方案快速选择指南

• •预算≤¥4万/周期：选基础ICSI+自然周期或微刺激方案
• •追求活产率且预算¥5–7万：标准ICSI+囊胚培养+单胚移植
• •有遗传病史或反复失败：首选高端档+PGT-A+个体化内膜准备